Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Closes Sales of 16 Non-Core Meds to Germany’s Cheplapharm
January 6, 2021
- Hisamitsu’s Osteoarthritis Patch Drug Enters PIII in US
January 6, 2021
- Kobayashi Kako Corrects Number of Health Damages from Itraconazole Mix-Up
January 6, 2021
- Drug Makers, Wholesalers Brace for Second Emergency Declaration in Japan
January 6, 2021
- Ono, Prof. Honjo Disagree About Validity of Patent Royalty Rate for Opdivo
January 6, 2021
- Daiichi Sankyo Files Sakigake-Designated Oncolytic Virus in Japan After Overcoming Manufacturing Issues
January 6, 2021
- Fuji Pharma Files Natural Progesterone Drug in Japan for Menopausal Disorders
January 5, 2021
- Kobayashi Kako Adds 2 APIs to Class II Recall List, Meiji/Elmed Products
December 28, 2020
- AstraZeneca to Accelerate Growth of Forxiga with Heart Failure Use, Gets Head Start in Arena before Rival Jardiance
December 28, 2020
- US FDA Lifts Clinical Hold for Audentes’ Gene Therapy AT132: Astellas
December 28, 2020
- Opdivo Misses Primary Targets in PIII for Glioblastoma Multiforme: BMS
December 28, 2020
- Kobayashi Kako Recalls 12 More APIs after On-Site Inspections
December 25, 2020
- Daiichi Sankyo Espha Stops Supply of 3 APIs after Kobayashi Kako Mix-up
December 25, 2020
- Mitsubishi Tanabe to Revise Company Rules for Common-Law Marriages, Same-Sex Relationships
December 25, 2020
- 49 APIs Listed in 2020, 10 Billion-Plus Yen Peak Sales Projected for 17: Jiho Tally
December 24, 2020
- Kyowa Kirin Adjusts Shipment of Depakene after Kobayashi Kako Drug Mix-Up
December 24, 2020
- Sales Rep Promotions Down Both in GP, HP Markets in October: Intage
December 24, 2020
- Sosei, Captor to Collaborate on Targeted GPCR Degradation
December 23, 2020
- Axcelead Looks to Unearth New Drugs from Takeda’s Legacy Assets, 5-Plus Collaborations Ongoing
December 23, 2020
- Maruho Taps Atsushi Sugita as New President
December 23, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…